Complement: An efficient sword of innate immunity

Contributions to Microbiology

Volumn 15, Issue , 2008, Pages 78-100

  Rambach, G ^a   Wurzner R ^a   Speth, C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR;

ANIMAL; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; COMPLEMENT ACTIVATION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; MYCOSIS; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, NATURAL; MYCOSES; NEOPLASMS; RECEPTORS, COMPLEMENT; SIGNAL TRANSDUCTION; VACCINATION;

EID: 49449095849     PISSN: 14209519     EISSN: 1662291X     Source Type: Book Series    
DOI: 10.1159/000136316     Document Type: Review

References (58)

1. Prodinger WM, Würzner R, Stoiber H, Dierich MP: Complement; in Paul WE (ed): Fundamental Immunology. Philadelphia, Lippincott, 2003, pp 1077-1104.
2. Morgan BP, Gasque P: Extrahepatic complement biosynthesis: Where, when and why? Clin Exp Immunol 1997;107:1-7.
3. Bruder C, Hagleitner M, Darlington G, Mohsenipour I, Würzner R, Höllmüller I, Stoiber H, Lass-Flörl C, Dierich MP, Speth C: HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol Immunol 2004;403:949-961.
4. Morgan BP: Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989;264:1-14.
5. Krych-Goldberg M, Atkinson JP: Structure-function relationships of complement receptor type 1. Immunol Rev 2001;180:112-122.
6. Chen Z, Koralov SB, Kelsoe G: Regulation of the humoral immune responses by CD21/CD35. Immunol Rev 2000;176:194-204.
7. Fearon DT, Carroll MC: Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 2000;18:393-422.
8. Ehlers MR: CR3:a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect 2000;2:289-294.
9. Helmy KY, Katschke KJ, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M: CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 2006;124:915-927.
10. Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, Gatto D, Sebbel P, Beerli RR, Sonderegger I, Kopf M, Saudan P, Bachmann MF: VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest 2006;116:2817-2826.
11. Gerard NP, Gerard C: The chemotactic receptor for human C5a anaphylatoxin. Nature 1991;349:614-617.
12. Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, Gerard C: An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem 2005;280:39677-39680.
13. Eggleton P, Reid KB, Tenner AJ: C1q-how many functions? How many receptors? Trends Cell Biol 1998;8:428-431.
14. Henson PM, Bratton DL, Fadok VA: The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001;2:627-633.
15. Edelson BT, Stricker TP, Li Z, Dickeson SK, Shepherd VL, Santoro SA, Zutter MM: Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood 2006;107:143-150.
16. Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, McCallum SA, Embuscado L, DeForge L, Hass PE, van Lookeren Campagne M: Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 2006;444:217-220.
17. Song WC: Complement regulatory proteins and autoimmunity. Autoimmunity 2006;39:403-410.
18. Reis ES, Falcão DA, Isaac L: Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol 2006;63:155-168.
19. Eisen DP, Stubbs J, Spilsbury D, Carnie J, Leydon J, Howden BP: Low mannose-binding lectin complement activation function is associated with predisposition to Legionnaires' disease. Clin Exp Immunol 2007;149:97-102.
20. Manuel O, Pascual M, Trendelenburg M, Meylan PR: Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007;83:359-362.
21. Tran CT, Kjeldsen K, Haunsø S, Høiby N, Johansen HK, Christiansen M: Mannan-binding lectin is a determinant of survival in infective endocarditis. Clin Exp Immunol 2007;148:101-105.
22. Smithson A, Muñoz A, Suarez B, Soto SM, Perello R, Soriano A, Martinez JA, Vila J, Horcajada JP, Mensa J, Lozano F: Association between mannose-binding lectin deficiency and septic shock following acute pyelonephritis due to Escherichia coli. Clin Vaccine Immunol 2007;14:256-261.
23. Robson MG, Walport MJ: Pathogenesis of systemic lupus erythematosus (SLE). Clin Exp Allergy 2001;31:678-685.
24. Carugati A, Pappalardo E, Zingale LC, Cicardi M: C1-inhibitor deficiency and angioedema. Mol Immunol 2001;38:161-173.
25. Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP: Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:111-122.
26. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M: Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007;204:1249-1256.
27. Hill A, Richards SJ, Hillmen P: Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007;137:181-192.
28. Couser WG, Nangaku M: Cellular and molecular biology of membranous nephropathy. J Nephrol 2006;19:699-705.
29. Trouw LA, Daha MR: Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther 2005;5:243-251.
30. van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Döpp EA, Dijkstra CD: Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J Neuroimmunol 1996;70:145-152.
31. Land WG: Innate immunity-mediated allograft rejection and strategies to prevent it. Transplant Proc 2007;39:667-672.
32. Speth C, Dierich MP, Sopper S: HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol Immunol 2005;42:213-228.
33. Speth C, Dierich MP, Gasque P: Neuroinvasion by pathogens: a key role of the complement system. Mol Immunol 2002;38:669-679.
34. Goldfarb RD, Parrillo JE: Complement. Crit Care Med 2005;33:482-484.
35. Hoesel LM, Niederbichler AD, Ward PA: Complement-related molecular events in sepsis leading to heart failure. Mol Immunol 2007;44:95-102.
36. Würzner R: Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 1999;36:249-260.
37. Hong YQ, Ghebrehiwet B: Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Clin Immunol Immunopathol 1992;62:133-138.
38. Marikovsky M, Parizade M, Arnon R, Fishelson Z: Complement regulation on the surface of cultured schistosomula and adult worms of Schistosoma mansoni. Eur J Immunol 1990;20:221-227.
39. Joiner KA: Complement evasion by bacteria and parasites. Annu Rev Microbiol 1988;42:201-230.
40. Russo DC, Williams DJ, Grab DJ: Mechanisms for the elimination of potentially lytic complement-fixing variable surface glycoprotein antibody-complexes in Trypanosoma brucei. Parasitol Res 1994;80:487-492.
41. Marschang P, Sodroski J, Würzner R, Dierich MP: Decay-accelerating factor (CD55) protects human immunodeficiency virus type I from inactivation by human complement. Eur J Immunol 1995;25:285-290.
42. Stoiber H, Pinter C, Siccardi AG, Clivio A, Dierich MP: Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H. J Exp Med 1996;183:307-310.
43. Blom AM, Villoutreix BO, Dahlbäck B: Complement inhibitor C4b-binding protein - friend of foe in the innate immune system? Mol Immunol 2004;40:1333-1346.
44. Jha P, Kotwal GJ: Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J Biosci 2003;28:265-271.
45. Bergmann-Leitner ES, Leitner WW, Tsokos GC: Complement 3d: from molecular adjuvant to target of immune escape mechanisms. Clin Immunol 2006;121:177-185.
46. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R: Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 2007;178:5991-5998.
47. Rozanov DV, Savinov AY, Golubkov VS, Tomlinson S, Strongin AY: Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res 2006;66:6258-6263.
48. Gill DB, Atkinson JP: CD46 in Neisseria pathogenesis. Trends Mol Med 2004;10:459-465.
49. Speth C, Prodinger WM, Würzner R, Stoiber H, Dierich MP: Complement; in Paul WE (ed): Fundamental Immunology. Philadelphia, Lippincott, 2007, in press.
50. Liu D, Zhang D, Scafidi J, Wu X, Cramer CC, Davis AE 3rd: C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 2005;105:2350-2355.
51. Mikesch JH, Buerger H, Simon R, Brandt B: Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta 2006;1766:42-52.
52. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD: Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 2003;63:9023-9031.
53. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP: An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 2003;101:1071-1079.
54. Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD: Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2004;10:53-60.
55. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, Peng KW: Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006;34:713-720.
56. Ni S, Gaggar A, Di Paolo N, Li ZY, Liu Y, Strauss R, Sova P, Morihara J, Feng Q, Kiviat N, Touré P, Sow PS, Lieber A: Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther 2006;13:1072-1081.
57. Suominen E, Toivonen R, Grenman R, Savontaus M: Head and neck cancer cells are efficiently infected by Ad5/35 hybrid virus. J Gene Med 2006;8:1223-1231.
58. Fearon DT: Innate immunity-beginning to fulfill its promise? Nat Immunol 2000;1:102-103.